GlobalData on MSN18h
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...
MassDevice15h
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Frontiers39m
Early Phase Clinical Trials for the Development of Novel Immunotherapeutic Anti-cancer Agents
Drug development in oncology is historically challenging, exhibiting a very high attrition rate, with low rates of approval for novel treatments when compared to other therapeutic areas. At present, ...
Investor's Business Daily on MSN12h
Intuitive Surgical's Earnings Are On Deck. Will Its 41% Surge Remain Intact?
Intuitive Surgical stock is flirting with its 50-day line as the robotic surgery behemoth approaches its third-quarter report late Thursday.